本文關鍵詞：腦心通膠囊治療缺血性心肌病的臨床研究　出處：《中國臨床藥理學雜志》2017年15期 　論文類型：期刊論文

  更多相關文章： 腦心通膠囊 缺血性心肌病 左心室重塑 安全性

【摘要】：目的觀察腦心通膠囊治療缺血性心肌病的臨床療效及安全性。方法將86例缺血性心肌病患者隨機分為對照組43例和試驗組43例。對照組予以血管緊張素受體拮抗藥、利尿藥及洋地黃等常規(guī)基礎治療;試驗組在對照組治療的基礎上,予以腦心通1.6 g,tid,口服。2組患者均治療6個月。比較2組患者的臨床療效、左心室舒張末期內(nèi)徑、左心室收縮末期內(nèi)徑、左心室射血分數(shù)(LVEF)以及藥物不良反應的發(fā)生情況。結果治療后,試驗組和對照組的總有效率分別為88.37%(38/43例)和72.09%(31/43例),差異有統(tǒng)計學意義(P0.05)。治療后,對照組和試驗組的左心室舒張末期內(nèi)徑分別為(33.16±6.43)和(27.98±5.62)mm,收縮末期內(nèi)徑分別為(53.23±5.39)和(47.36±1.56)mm,LVEF分別為(47.44±5.73)%和(57.61±5.12)%,差異均有統(tǒng)計學意義(均P0.05)。試驗組的藥物不良反應有惡心和嘔吐,對照組的藥物不良反應有惡心、嘔吐和腹瀉。試驗組與對照組的藥物不良反應發(fā)生率分別為6.98%和9.30%,差異無統(tǒng)計學意義(P0.05)。結論腦心通膠囊治療改善缺血性心肌病的臨床療效確切,可顯著改善患者的心功能,且不增加藥物不良反應的發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of Naoxintong capsule in the treatment of ischemic cardiomyopathy. Methods 86 patients with ischemic cardiomyopathy were randomly divided into control group (n = 43) and experimental group (n = 43). Body antagonists. Diuretics, digitalis and other routine basic treatment; The experimental group was treated with Naoxintong 1.6 g / d on the basis of the control group and treated for 6 months in the oral .2 group. The clinical efficacy and left ventricular end-diastolic diameter were compared between the two groups. Left ventricular end-systolic diameter, left ventricular ejection fraction (LVEF) and adverse drug reactions. The total effective rates of the test group and the control group were 88.37 and 72.09, respectively. The difference was statistically significant (P 0.05). The left ventricular end-diastolic diameter of the control group and the experimental group were 33.16 鹵6.43) and 27.98 鹵5.62 mm respectively. The end systolic diameters were 53.23 鹵5.39) and 47.36 鹵1.56 mm respectively. LVEF was 47.44 鹵5.73% and 57.61 鹵5.12%, respectively. The difference was statistically significant (P 0.05). The adverse drug reactions in the test group were nausea and vomiting. The adverse drug reactions in the control group were nausea, vomiting and diarrhea. The incidence of adverse drug reactions in the trial group and the control group were 6.98% and 9.30% respectively. Conclusion Naoxintong capsule is effective in the treatment of ischemic cardiomyopathy, it can significantly improve the cardiac function of patients, and does not increase the incidence of adverse drug reactions.
【作者單位】： 勝利石油管理局勝利醫(yī)院心內(nèi)科;勝利石油管理局勝利醫(yī)院精神衛(wèi)生康復中心;山東大學第二醫(yī)院心內(nèi)科;
【基金】：山東省自然科學基金資助項目(2014ZRE27592)
【分類號】：R259
【正文快照】： (1.勝利石油管理局勝利醫(yī)院,a.心內(nèi)科;b.精神衛(wèi)生康復中心,山東東營257055;2.山東大學第二醫(yī)院心內(nèi)科,濟南250033)LI Zhong-han1a,SUN Yu-yan1a,SHI Lei1b,CHEN Hui-qiang2(1.a.Department of Cardiology;b.Mental Health Rehabilitation Center,Shengli Hospital of Shengli

【參考文獻】

相關期刊論文 前2條

1 廖燕玲;蒙蘭青;林麗飛;;腦心通聯(lián)合注射用丹參多酚酸鹽對老年急性腦梗死的影響[J];中國生化藥物雜志;2014年05期

2 賀志偉;李力明;鄒迪貴;賀芙妮;;腦心通對急性心肌梗死患者再灌注后心肌和微血管的影響觀察[J];中國實用醫(yī)藥;2010年17期

【共引文獻】

相關期刊論文 前10條

1 李中山;史磊;孫玉巖;陳會強;;腦心通膠囊治療缺血性心肌病的臨床研究[J];中國臨床藥理學雜志;2017年15期

2 張麗芳;劉濤;張鳳英;;丹參多酚酸聯(lián)合高氧液治療急性進展性腦梗死療效及機制研究[J];河北醫(yī)藥;2017年13期

3 張奇;劉偉文;;用丹參多酚酸聯(lián)合針刺療法治療腦梗死的效果評析[J];當代醫(yī)藥論叢;2017年11期

4 吳文琴;皮海菊;秦雪琴;楊X椙，

本文編號：1392037